<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781439</url>
  </required_header>
  <id_info>
    <org_study_id>50/CN-HĐĐĐ</org_study_id>
    <nct_id>NCT04781439</nct_id>
  </id_info>
  <brief_title>The Effect of Early Switching From Intravenous to Oral Antibiotics Therapy</brief_title>
  <official_title>The Effect of Early Switching From Intravenous to Oral Antibiotics Therapy: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gia Dinh People Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gia Dinh People Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, many studies showed the great benefits of switching from IV to PO antibiotics in&#xD;
      some infectious diseases, especially skin and soft tissue, urinary tract, respiratory tract,&#xD;
      gallbladder, and biliary tract infection. Higher level of evidence is necessary to confirm&#xD;
      the benefit of early switching protocol in infectious condition management. Therefore, we&#xD;
      conducted a clinical trial to investigate the effectiveness and cost of IV-to-PO antibiotic&#xD;
      switch therapy in some surgical infection conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: The benefit of early switching from intravenous (IV) to oral (PO)was raising&#xD;
      from the last decade. This randomized clinical trial was to evaluate the effect of early&#xD;
      switching from IV to PO antibiotics on the outcome of surgical patients at a public hospital.&#xD;
&#xD;
      Methods: Patients admitted for a therapeutic antibiotic to orthopedic and general surgery&#xD;
      conditions were randomly assigned to three groups: control (non-switching), early switching&#xD;
      (within 48-72 hours), and late switching (after 72 hours). The rate of effectiveness of each&#xD;
      arm, length of hospital stay, length of IV antibiotics, and cost were recorded prospectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Actual">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of effectiveness</measure>
    <time_frame>3 months</time_frame>
    <description>rate of effectiveness of the infection treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>length of hospital stay after starting the antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of IV antibiotics</measure>
    <time_frame>3 months</time_frame>
    <description>length of IV antibiotics usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>cost of antibiotics</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Skin and Subcutaneous Tissue Infection</condition>
  <arm_group>
    <arm_group_label>non-switching</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV-to-PO conversion within 48-72 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early switching</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV-to-PO conversion after 72 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>late switching</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IV-to-PO conversion of antibiotics</intervention_name>
    <description>IV-to-PO switching of antibiotics treatment</description>
    <arm_group_label>IV-to-PO conversion after 72 hours</arm_group_label>
    <arm_group_label>IV-to-PO conversion within 48-72 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  on the second day of IV antibiotic&#xD;
&#xD;
          -  no difficulties on taking oral medication&#xD;
&#xD;
          -  clinical improvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  n/a&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Nguyen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gia Dinh People Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gia Dinh people hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>effectiveness</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

